Please login to the form below

Not currently logged in
Email:
Password:

Lynparza

This page shows the latest Lynparza news and features for those working in and with pharma, biotech and healthcare.

AZ nabs US approval for new leukaemia drug Lumoxiti

AZ nabs US approval for new leukaemia drug Lumoxiti

cancer. However, AZ has two other targeted drugs – PARP inhibitor Lynparza (olaparib) for breast and ovarian cancer and EGFR blocker Tagrisso (osimertinib) – still in the growth phase.

Latest news

More from news
Approximately 22 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • 30 Women Leaders in UK Healthcare

    for Lynparza, the first in class PARP inhibitor now approved in ovarian and breast cancers.

  • Transforming times at AstraZeneca Transforming times at AstraZeneca

    in the EGFR-TK gene and Lynparza, which is approved to treat ovarian cancer patients with the BRCA mutation. “ ... 2015. “ Lynparza is for a very specific population of platinum sensitive relapse patients,” explains Anson. “

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics